Innate Pharma SA ADR IPHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPHA is a good fit for your portfolio.
News
-
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
-
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
-
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
-
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
-
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
-
Innate Pharma Announces Its Participation in Upcoming Investor Conference
-
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
-
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Trading Information
- Previous Close Price
- $2.61
- Day Range
- $2.51–2.64
- 52-Week Range
- $1.81–3.57
- Bid/Ask
- $2.42 / $2.65
- Market Cap
- $213.42 Mil
- Volume/Avg
- 10,369 / 9,001
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 179
- Website
- https://www.innate-pharma.com
Comparables
Valuation
|
Metric
|
IPHA
|
FUSN
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.68 | 7.52 | 3.15 |
Price/Sales | 3.74 | 768.05 | 339.29 |
Price/Cash Flow | — | — | — |
Price/Earnings
IPHA
FUSN
CLDX
Financial Strength
|
Metric
|
IPHA
|
FUSN
|
CLDX
|
|---|---|---|---|
Quick Ratio | 3.51 | 10.37 | 31.44 |
Current Ratio | 3.73 | 10.64 | 31.77 |
Interest Coverage | −15.79 | −18.82 | — |
Quick Ratio
IPHA
FUSN
CLDX
Profitability
|
Metric
|
IPHA
|
FUSN
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −2.51% | −33.14% | −23.59% |
Return on Equity (Normalized) | −9.04% | −43.87% | −25.21% |
Return on Invested Capital (Normalized) | −7.88% | −36.42% | −25.04% |
Return on Assets
IPHA
FUSN
CLDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ngrkyssn | Trjk | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dcwtwvkg | Hxvxmn | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mcmkwgyc | Qswyv | $107.6 Bil | |
MRNA
| Moderna Inc | Yzfwyddd | Mkjl | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Vtbzqvlk | Xps | $22.3 Bil | |
ARGX
| argenx SE ADR | Vtrdvgyqr | Vtckk | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sdxzpwhkb | Zgpnw | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dfxntns | Ppvyj | $15.3 Bil | |
INCY
| Incyte Corp | Wtjknxkw | Lgwgl | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wrshhcgrk | Lrknkl | $12.8 Bil |